A Phase 3 Randomized Study of Cystectomy plus Perioperative Pembrolizumab versus Cystectomy Alone in Cisplatin-ineligible Participants with Muscleinvasive Bladder Cancer (KEYNOTE-905)

Brief description of study

This is a research study involving the drug pembrolizumab. The purpose of this study is to: o See if pembrolizumab before and after surgery is more effective than surgery alone in patients with muscle-invasive bladder cancer (MIBC). This will be measured by tissue samples that are taken during surgery as well as imaging performed at different time points. o Test the safety of the study drug, pembrolizumab, given before and after surgery. o See how well your body handles pembrolizumab, before and after surgery. o See if pembrolizumab and surgery, compared to surgery alone, helps patients have a better quality of life. o See if pembrolizumab helps patients live longer.

Clinical Study Identifier: s18-01490
ClinicalTrials.gov Identifier: NCT03924895
Principal Investigator: Arjun Vasant Balar.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.